UTRx is pleased to announce that we have filed 5 new patent application mid February 2025 with the USPTO and 1 PCT filed early February 2025. The new IPs cover our The PCT covers our novel TEAD1 and YAP1 drug targeting hippo pathway driven cancer
Read the latest interview of our PI and CEO, Dr Awah with Susan Schulz on UTR Therapeutics Inc. progress on advancing our novel drugs through the regulatory pathways and the discovery of UTR novel mRNA platform and the many exciting things it has created. Many thanks to Seema Kumar , the CEO of CURE and […]
breakthrough medicine for deadly diseases. Cure will re-broadcast this interview, the Tuesday talks on Tuesday 16th July, 2024 at 12:30 PM ET. It will air it across Twitter @cure345, on LinkedIn and on cure new website at www.wewillcure.com Cure. UTR Therapeutics Seema Kumar# Novel mRNA drugs, # breakthrough medicine for deadly diseases.
Chidiebere Awah, MD, PhD, was a student in his native Nigeria when he realized that chemotherapies weren’t curing patients with advanced cancers and they needed different therapies. Throughout his academic travels — which brought him to Madrid, Cambridge in the UK, Hanover, Germany and ultimately New York — he came upon two striking realizations that […]
Event by Cure. UTR Therapeutics CEO and genome engineer Dr. Chidiebere Awah joins Cure CEO Seema Kumar to explain the science and how he developed his company to deploy first–in–class mRNA overwriting therapies and what this means for a wide range of diseases and disorders.
Event hosted by Cure. February 27, 2024 – February 27, 2024 Online event About this event This week on Tuesday Talks, learn the latest on how genomeengineers are using mRNA therapies to build powerful new tools to treatcancer, neurodegenerative disorders, metabolic diseases, and more.UTR Therapeutics CEO and genome engineer Dr. Chidiebere Awah will join Cure CEO […]
On July 31, 2023 The pre IND product UTRxM1-18 targeting c-MYC in TNBC and across other cancers received thorough feedback and guidance from the FDA. Thanks to all our Team members, mentors, funders and Thermofisher Inc and all our strategic partners who support us as we progress.
40 Under 40 in Cancer is an awards initiative to identify and recognize the contributions being made across the field of cancer by rising stars and emerging leaders under the age of 40 years. Finalists and awardees will be selected by a panel of reviewers from across diverse roles in oncology.
Chidiebere Awah MD PhD receives 40 under 40 in Cancer
Two Minority-Led Life Science Startup Companies Awarded $250,000 Grants and Access to Cure® Ecosystem